Results 11 to 20 of about 602,416 (352)

Exploration of the antibody–drug conjugate clinical landscape

mAbs, 2023
The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial recent developmental investment and subsequent drug approvals over the past 6 years. In November 2022, ElahereTM became the latest ADC to be approved by the US Food and
Heather Maecker, Vidya Jonnalagadda, Sunil Bhakta, Vasu Jammalamadaka, Jagath R. Junutula   +4 more
doaj   +2 more sources

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting [PDF]

Frontiers in Immunology, 2023
Cancerous B cells are almost indistinguishable from their non-malignant counterparts regarding their surface antigen expression. Accordingly, the challenge to be faced consists in elimination of the malignant B cell population while maintaining a ...
Katrin Schoenfeld, Julia Harwardt, Jan Habermann, Adrian Elter, Harald Kolmar, Harald Kolmar   +5 more
doaj   +2 more sources

HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer [PDF]

Cancer Medicine
Background HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other ...
Seohyuk Lee, Adriana M. Kahn, Mariya Rozenblit, Mridula A. George, Cristina Naranjo Ortiz, Maryam B. Lustberg   +5 more
doaj   +2 more sources

Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugate targeting claudin-6, called TORL-1-23.
Laura Matuszewska, Caitlynn Cooper, Victoria Sattarova, Wassef Chanbour, Evan Meyer, Vania Rashidi   +5 more
doaj   +2 more sources

Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy

Journal of Extracellular Vesicles, 2021
Antibody‐drug conjugates (ADCs) are a new class of anti‐cancer drugs that consist of a monoclonal antibody, a highly potent small‐molecule cytotoxic drug, and a chemical linker between the two. ADCs can selectively deliver cytotoxic drugs to cancer cells
Mark Barok, Maija Puhka, Narjes Yazdi, Heikki Joensuu   +3 more
doaj   +2 more sources

Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat [PDF]

Journal of Immunotherapy and Precision Oncology
Kathy L. Chan, Saadia A. Faiz, Ajay Sheshadri   +2 more
doaj   +2 more sources

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy

Pharmaceuticals, 2022
Although there have been extensive research and progress on the discovery of anticancer drug over the years, the application of these drugs as stand-alone therapy has been limited by their off-target toxicities, poor pharmacokinetic properties, and low ...
Audrey Nathania Johan, Yi Li
doaj   +1 more source

Antibody–Drug Conjugate to Treat Meningiomas

Pharmaceuticals, 2021
Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control ...
Kai Chen, Yingnan Si, Jianfa Ou, Jia-Shiung Guan, Seulhee Kim, Patrick Ernst, Ya Zhang, Lufang Zhou, Xiaosi Han, Xiaoguang (Margaret) Liu   +9 more
doaj   +1 more source

AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody–Drug Conjugate Production

Bioconjugate chemistry, 2023
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody–drug conjugate (ADC) community.
Tomohiro Fujii, Yutaka Matsuda, Takuya Seki, Natsuki Shikida, Yusuke Iwai, Yuri Ooba, Kazutoshi Takahashi, M. Isokawa, Sayaka Kawaguchi, Noriko Hatada, Tomohiro Watanabe, Rika Takasugi, Akira Nakayama, K. Shimbo, B. Mendelsohn, T. Okuzumi, Kei Yamada   +16 more
semanticscholar   +1 more source

Specific ablation of PDGFRβ-overexpressing pericytes with antibody-drug conjugate potently inhibits pathologic ocular neovascularization in mouse models

Communications Medicine, 2021
Lee et al. use an antibody-drug conjugate to treat pathologic ocular neovascularization in mouse models. The antibody-drug conjugate targets PDGFRβ-expressing pericytes, with similar therapeutic effects to an anti-VEGF agent and with limited unwanted ...
Seok Jae Lee, Soohyun Kim, Dong Hyun Jo, Chang Sik Cho, Su Ree Kim, Dongmin Kang, Jisu Chae, Duck Kyun Yoo, Suji Ha, Junho Chung, Jeong Hun Kim   +10 more
doaj   +1 more source